Fidelity Investments’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Fidelity Investments’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-430,672	Closed	-$1.53M	–	4374
2019 Q1	$1.53M	Sell	430,672 -144,081	-25%	-$782K	﹤0.01%	2360
2018 Q4	$2.28M	Sell	574,753 -200	-0%	-$2.56K	﹤0.01%	2247
2018 Q3	$11.4M	Sell	574,953 -553,108	-49%	-$14M	﹤0.01%	1896
2018 Q2	$35.8M	Buy	1,128,061 +930,159	+470%	+$33.5M	﹤0.01%	1443
2018 Q1	$7.32M	Hold	197,902	–	–	﹤0.01%	2046
2017 Q4	$15.6M	Buy	+197,902	New	+$14.6M	﹤0.01%	1807

Other funds holding MLNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Fidelity Investments's MLNT Position: Q2 2019 in Review

Fidelity Investments sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 430,672 shares — an estimated $1.53M sold.

Fidelity Investments first reported a position in MLNT in Q4 2017 and held it in 6 quarters. The position peaked at $35.8M in Q2 2018. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

Fidelity Investments reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Fidelity Investments sold 430,672 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.53M.
Fidelity Investments first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
Fidelity Investments's Melinta Therapeutics, Inc. Common Stock position peaked at $35.8M in Q2 2018.
53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Fidelity Investments's 13F filing for Q2 2019, filed 13 Aug 2019.